Although the recently reported phase 2 trial and the currently ongoing phase 3 trial of baricitinib have focused on non-renal SLE patients, considering the role of the JAK/STAT pathway associated with SLE pathogenesis, baricitinib and more selective novel JAK inhibitors could be applied to SLE patients with other clinical manifestations including renal involvements based on results of this study. This evidence concerns the gene SOAT1 and systemic lupus erythematosus.